Abstract
Objective: FDG-PET has been used for cancer screening, mainly in East-Asia, and cancers are found not infrequently. However, their stages have not been clarified. We examined the detection rates of various cancers using whole-body PET for the screening of cancers in asymptomatic individuals, focusing on their clinical and pathological stages.Methods: Whole-body PET was obtained as a part of our cancer screening program among 3,426 healthy subjects. All subjects participated in a course of PET examination in conjunction with conventional examinations including a medical questionnaire, tumor markers, immunological fecal occult blood test, neck and abdominal ultrasonography and whole body computed tomography. A diagnosis and staging was obtained by an analysis of the pathological findings or by an analysis of the clinical follow-up data.Results: Malignant tumors were discovered in 65 lesions found in 3,426 participants (1.90%). The PET findings were true-positive in 46 of the 65 cancer cases. The cancers were found in the following organs: the colon 14; thyroid gland 10; stomach 7; lung 5; liver 3; breast 2; and one each in the kidney, gallbladder, esophagus, pancreas and retroperitoneum. The stages were as follows: stage 0 5, stage I 17, stage II 10, stage III 7, and stage IV 6. One was an unknown primary. There were 19 false-negative findings (0.6%) on PET. Six cancers (0.18%) were missed in our screening program.Conclusions: PET imaging has the potential to detect a wide variety of cancers at potentially curative stages. Most PET-negative cancers are early stage cancers, and thus can be detected using other conventional examinations such as endoscopy.
Article PDF
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Avoid common mistakes on your manuscript.
References
Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.Eur J Nucl Med 1996; 23: 1641–1674.
Adler LP, Blair HF, Makley JT, Williams RP, Joyce MJ, Leisure G, et al. Noninvasive grading of musculoskeletal tumors using PET.J Nucl Med 1991; 32: 1508–1512.
Price P, Jones T. Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy?Eur J Cancer 1995; 31A: 1924–1927.
Okada J, Oonishi H, Yoshikawa K, Itami J, Uno K, Imaseki K, et al. FDG-PET for predicting the prognosis of malignant lymphoma.Ann Nucl Med 1994; 8: 187–191.
Nakata B, Chung YS, Nishimura S, Nishihara T, Sakurai Y, Sawada T, et al.18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma.Cancer 1997; 79: 695–699.
Oshida M, Uno K, Suzuki M, Nagashima T, Hashimoto H, Yagata H, et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro18F-D-glucose.Cancer 1998; 82: 2227–2234.
Guerrero TM, Hoffman FJ, Dahlbom M, Cutler PD, Hawkins RA, Phelps ME. Characterization of a whole body imaging technique for PET.IEEE Trans Nucl Sci 1990; 37 (2): 676–680.
Conti PS, Lilien DJ, Hawley K, Keppler J, Grafton ST, Bading JR. PET and 18-[F] FDG in oncology: a clinical update.Nucl Med Biol 1996; 23: 717–735.
Delbeke D. Oncological applications of FDG PET imaging: brain tumors, colorectal cancer lymphoma and melanoma.J Nucl Med 1999; 40: 591–603.
Lassen U, Daugaard G, Eigtved A, Damgaard K, Friberg L.18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT).Eur J Cancer 1999; 35: 1076–1082.
Yasuda S, Shohtsu A. Cancer screening with whole-body18F-fluorodeoxyglucose positron-emission tomography.The Lancet 1997; 350: 1819.
Chen YK, Ding HJY, Su CT, Shen YY, Chen LK, Liao AC, et al. Application of PET and PET/CT imaging for Cancer Screening.Anticancer Res 2004; 24: 4103–4108.
Shen YY, Su CT, Chen GJS, Chen YK, Liao ACF, Tsai FS. The value of18F-fluorodeoxyglucose positron emission tomography with the additional help of tumor markers in cancer screening.Neoplasma 2003; 50 (3): 217–221.
Ide M. Cancer screening with FDG-PET.Jpn J Clin Radiol 2004; 49: 835–840.
Kao CH, Kwan AS, Kwan JK, Chow MJ. The role of18F-fluorodeoxyglucose positron emission tomography in cancer screening—A preliminary report.Oncology Reports 2001; 8: 1145–1148.
Yasuda S, Ide M, Fujii H, Nakahara T, Mochizuki Y, Takahashi W, et al. Application of positron emission tomography imaging to cancer screening.Br J Cancer 2000; 83 (12): 1607–1611.
Jinnouchi S. Could FDG-PET change the conventional scheme of cancer screening?Jpn J Clin Radiol 2004; 49: 855–863.
Engel H, Steinert H, Buck A, Berthold T, Huch Boni RA, von Schulthess GK. Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations.J Nucl Med 1996; 37: 441–446.
Sobin LH, Wittekind CH, eds.TNM Classification of Malignant Tumors, 5th ed. New York; John Wiley & Sons, Inc., 1997.
Japan Cancer Society.The Statistics of Cancer Screening 2003. Tokyo; Japan Cancer Society, 2003.
Japanese Society of Gastroenterological Mass Survey.Annual report of gastroenterological mass survey in Japan 2002. Tokyo; Japanese Society of Gastroenterological Mass Survey, 2002.
Uno K, Woo J, Suzuki T, Suzuki H, Kosaka N, Matsuo Y, et al. What are the problems of cancer screening using FDG-PET?Jpn J Clin Radiol 2004; 49: 841–846.
Chung WY, Chang HS, Kim EK, Park CS. Ultrasonographic mass screening for thyroid carcinoma: a study in women scheduled to undergo a breast examination.Surgery Today 2001; 31: 763–767.
Siironen P, Louhimo J, Nordling S, Ristimäki A, Mäenpää H, Haapiainen R, et al. Prognostic Factors in Papillary Thyroid Cancer: An Evaluation of 601 Consecutive Patients.Tumor Biology 2005; 26: 57–64.
Sobue T, Moriyama N, Kaneko M, Kusumoto M, Kobayashi T, Tsuchiya R, et al. Screening for lung cancer with low-dose helical computed tomography: anti-lung cancer association project.J Clin Oncol 2002; 20 (4): 911–920.
Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasu K, Uno K. Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images.Lung Cancer 2004; 45 (1): 19–27.
Stahl A, Ott K, Weber WA, Becker K, Link T, Siewert JR, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings.Eur J Nucl Med 2003; 30 (2): 288–295.
Hofer C, Kubler H, Hartung R, Breul J, Avril N. Diagnosis and monitoring of urological tumors using positron emission tomography.Eur Urol 2001; 40 (5): 481–487.
Merminod T, Zulian GB. Multiple malignant tumours in the elderly.Crit Rev Oncol Hematol 2002; 43 (3): 227–230.
Nishiyama Y, Yamamoto Y, Yokoe K, Miyabe K, Ogawa T, Toyama Y, et al. FDG PET as a procedure for detecting simultaneous tumours in head and neck cancer patients.Nucl Med Commun 2005; 26: 239–244.
Ishimori T, Patel PV, Wahl RL. Detection of Unexpected Additional Primary Malignancies with PET/CT.J Nucl Med 2005; 46: 752–757.
Di Martino E, Nowak B, Hassan HA, Hausmann R, Adam G, Buell U, et al. Diagnosis and staging of head and neck cancer.Arch Otolaryngol Head Neck Surg 2000; 126: 1457–1461.
Robert G, Milne R. A Selphi study to establish national cost-effectiveness research priorities for positron emission tomography.Eur J Radiol 1999; 30: 54–60.
Vade A, Demos TC, Olson MC, Subbaiah P, Turbin RC, Vickery K, et al. Evaluation of image quality using 1∶1 pitch and 1.5∶1 pitch helical CT in children: a comparative study.Pediatr Radiol 1996; 26: 891–893.
Yasuda S, Ide M. PET and cancer screening.Ann Nucl Med 2005; 19 (3): 167–177.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ono, K., Ochiai, R., Yoshida, T. et al. The detection rates and tumor clinical/pathological stages of whole-body FDG-PET cancer screening. Ann Nucl Med 21, 65–72 (2007). https://doi.org/10.1007/BF03034001
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF03034001